Child's Nervous System

, Volume 32, Issue 11, pp 2061–2067 | Cite as

Spontaneous involution of pediatric low-grade gliomas: high expression of cannabinoid receptor 1 (CNR1) at the time of diagnosis may indicate involvement of the endocannabinoid system

  • Simone Treiger SredniEmail author
  • Chiang-Ching Huang
  • Mario Suzuki
  • Tatiana Pundy
  • Pauline Chou
  • Tadanori Tomita
Brief Communication



Pediatric low-grade gliomas (P-LGG) consist of a mixed group of brain tumors that correspond to the majority of CNS tumors in children. Notably, they may exhibit spontaneous involution after subtotal surgical removal (STR). In this study, we investigated molecular indicators of spontaneous involution in P-LGG.


We performed an integrated molecular analysis including high throughput gene expression (GE), microRNA (miRNA) expression data of primary, untreated tumors from patients with P-LGG who underwent STR at our institution, with at least 10 years follow-up.


We identified a set of protein-coding genes and miRNAs significantly differentially expressed in P-LGG that presented spontaneous involution (involution—I) or without progression (stable—S) after STR alone. The cannabinoid receptor 1 (CNR1 or CB1) gene (FC = 2.374; p value = 0.007) was at the top of the list and predicted to be regulated by hsa-miR-29b-3p (FC = −2.353, p value = 0.0001). CNR1 also showed a trend to be higher expressed in S/I by immunohistochemistry.


The P-LGG, which remained stable or that presented spontaneous involution after STR, showed significantly higher CNR1 expression at the time of diagnosis. We hypothesize that high expression levels of CNR1 provide tumor susceptibility to the antitumor effects of circulating endocannabinoids like anandamide, resulting in tumor involution. This corroborates with reports suggesting that CNR1 agonists and activators of the endocannabinoid system may represent therapeutic opportunities for children with LGG. We also suggest that CNR1 may be a prognostic marker for P-LGG. This is the first time spontaneous involution of P-LGG has been suggested to be induced by endocannabinoids.


CB1 miR-29b Anandamide Prognosis Brain neoplasm Children 



Funded by the Voices Against Brain Cancer Foundation (Fund#925432) and the Lurie Children’s Hospital Faculty Practice Plan Development Funding (Fund#931220).

We thank Kashyap Patel MS and Naira Margaryan DVM, Ph.D. for technical support; Aline T. Sredni and Jessica Jakubowski BS for editorial assistance.

Compliance with ethical standards

Conflicts of interest

The authors declare no conflicts of interest.


  1. 1.
    Wisoff JH, Sanford RA, Heier LA, Sposto R, Burger PC, Yates AJ, Holmes EJ, Kun LE (2011) Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children’s oncology group. Neurosurgery 68:1548–1554 discussion 1554-1545CrossRefPubMedGoogle Scholar
  2. 2.
    Scheinemann K, Bartels U, Tsangaris E, Hawkins C, Huang A, Dirks P, Fried I, Bouffet E, Tabori U (2011) Feasibility and efficacy of repeated chemotherapy for progressive pediatric low-grade gliomas. Pediatr Blood Cancer 57:84–88CrossRefPubMedGoogle Scholar
  3. 3.
    von Hornstein S, Kortmann RD, Pietsch T, Emser A, Warmuth-Metz M, Soerensen N, Straeter R, Graf N, Thieme B, Gnekow AK (2011) Impact of chemotherapy on disseminated low-grade glioma in children and adolescents: report from the HIT-LGG 1996 trial. Pediatr Blood Cancer 56:1046–1054CrossRefGoogle Scholar
  4. 4.
    Ogiwara H, Bowman RM, Tomita T (2012) Long-term follow-up of pediatric benign cerebellar astrocytomas. Neurosurgery 70:40–47 discussion 47-48CrossRefPubMedGoogle Scholar
  5. 5.
    Laprairie RB, Kelly ME, Denovan-Wright EM (2012) The dynamic nature of type 1 cannabinoid receptor (CB(1)) gene transcription. Br J Pharmacol 167:1583–1595CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Pisanti S, Picardi P, Pallottini V, Martini C, Petrosino S, Proto MC, Vitale M, Laezza C, Gazzerro P, Di Marzo V, Bifulco M (2015) Anandamide drives cell cycle progression through CB1 receptors in a rat model of synchronized liver regeneration. J Cell Physiol 230:2905–2914CrossRefPubMedGoogle Scholar
  7. 7.
    Velasco G, Sanchez C, Guzman M (2016) Anticancer mechanisms of cannabinoids. Curr Oncol 23:S23–S32CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Velasco G, Hernandez-Tiedra S, Davila D, Lorente M (2016) The use of cannabinoids as anticancer agents. Prog Neuro-Psychopharmacol Biol Psychiatry 64:259–266CrossRefGoogle Scholar
  9. 9.
    Ramer R, Hinz B (2015) New insights into antimetastatic and antiangiogenic effects of cannabinoids. Int Rev Cell Mol Biol 314:43–116CrossRefPubMedGoogle Scholar
  10. 10.
    Blazquez C, Casanova ML, Planas A, Gomez Del Pulgar T, Villanueva C, Fernandez-Acenero MJ, Aragones J, Huffman JW, Jorcano JL, Guzman M (2003) Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17:529–531PubMedGoogle Scholar
  11. 11.
    Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140:49–61CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Guzman M (2003) Cannabinoids: potential anticancer agents. Nat Rev Cancer 3:745–755CrossRefPubMedGoogle Scholar
  13. 13.
    Velasco G, Sanchez C, Guzman M (2012) Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 12:436–444CrossRefPubMedGoogle Scholar
  14. 14.
    Galve-Roperh I, Sanchez C, Cortes ML, Gomez del Pulgar T, Izquierdo M, Guzman M (2000) Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6:313–319CrossRefPubMedGoogle Scholar
  15. 15.
    Velasco G, Carracedo A, Blazquez C, Lorente M, Aguado T, Haro A, Sanchez C, Galve-Roperh I, Guzman M (2007) Cannabinoids and gliomas. Mol Neurobiol 36:60–67CrossRefPubMedGoogle Scholar
  16. 16.
    Torres S, Lorente M, Rodriguez-Fornes F, Hernandez-Tiedra S, Salazar M, Garcia-Taboada E, Barcia J, Guzman M, Velasco G (2011) A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10:90–103CrossRefPubMedGoogle Scholar
  17. 17.
    Blazquez C, Salazar M, Carracedo A, Lorente M, Egia A, Gonzalez-Feria L, Haro A, Velasco G, Guzman M (2008) Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res 68:1945–1952CrossRefPubMedGoogle Scholar
  18. 18.
    Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017–1066CrossRefPubMedGoogle Scholar
  19. 19.
    Chakravarti B, Ravi J, Ganju RK (2014) Cannabinoids as therapeutic agents in cancer: current status and future implications. Oncotarget 5:5852–5872CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bifulco M, Laezza C, Pisanti S, Gazzerro P (2006) Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148:123–135CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Simone Treiger Sredni
    • 1
    • 2
    • 3
    Email author
  • Chiang-Ching Huang
    • 4
  • Mario Suzuki
    • 1
    • 5
  • Tatiana Pundy
    • 1
  • Pauline Chou
    • 6
    • 7
  • Tadanori Tomita
    • 1
    • 2
  1. 1.Ann and Robert H. Lurie Children’s Hospital of Chicago, Division of Pediatric NeurosurgeryHospital of ChicagoChicagoUSA
  2. 2.Feinberg School of Medicine, Department of SurgeryNorthwestern UniversityChicagoUSA
  3. 3.Cancer Biology and EpigenomicsStanley Manne Children’s Research InstituteChicagoUSA
  4. 4.Joseph J. Zilber School of Public HealthUniversity of WisconsinMilwaukeeUSA
  5. 5.Department of NeurosurgeryJuntendo University, School of MedicineTokyoJapan
  6. 6.Ann and Robert H. Lurie Children’s Hospital of Chicago, Department of Pathology and Laboratory MedicineHospital of ChicagoChicagoUSA
  7. 7.Feinberg School of Medicine, Department of PediatricsNorthwestern UniversityChicagoUSA

Personalised recommendations